| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Cassava Sciences, Inc. (NASDAQ:SAVA) saw its stock price soar Friday, possibly amid rising short interest and an anticipated conference call to discuss recent developments.
What To Know: The company’s short percent of float has risen by 23.21% since its last report, with 16.13 million shares sold short, accounting for 35.89% of the total float. It would take traders an average of 4.75 days to cover their short positions based on the current trading volume.
What Else: Cassava Sciences is set to hold a conference call on Thursday August 8 2024, to discuss recent developments and provide a company update. Analysts expect the company to report earnings per share (EPS) loss of $0.40.
Earlier this week, Cassava also announced plans to extend its open-label extension trials for simufilam by up to 36 months. This will allow patients from previous trials to continue their treatment while awaiting Phase 3 trial results.
SAVA Price Action: Cassava Sciences shares were up by 24.4% at $29.21 according to Benzinga Pro.
See Also:
Image: Courtesy of Cassava Sciences.
Posted In: SAVA
